Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs). We collected the research results and related MeSH terms of denosumab from 2011 to 2021 through the Web of Science and PubMed, respectively. The literature was visualized and analyzed by CiteSpace and bibliometric online analysis platforms. The MeSH terms were biclustered using the Bibliographic Co-Occurrence Analysis System (BICOMB) and graph clustering toolkit (gCLUTO). The results show that the number of denosumab-related annual publications had increased from 51 to 215, with the United States leading and Amgen Inc. being the most influential in the past 10 years. Articles published in the Journal of Bone and Mineral Research had the highest total citations. Three scholars from Shinshu University in Matsumoto, Yukio Nakamura, Takako Suzuki, and Hiroyuki Kato, joined the field relatively late but produced the most. The clinical comparison and combination of denosumab with other drugs in the treatment of osteoporosis was the most significant focus of research. Drug withdrawal rebound and management strategies have gained more attention and controversy recently. MeSH analysis revealed eight major categories of research hotspots. Among them, exploring the multiple roles of the RANK-RANKL-OPG system in tumor progression, metastasis, and other diseases is the potential direction of future mechanism research. It is a valuable surgical topic to optimize the perioperative drug administration strategy for internal spinal fixation and orthopedic prosthesis implantation. Taken together, the advantages of denosumab were broad and cost-effective. However, there were still problems such as osteonecrosis of the jaw, severe hypocalcemia, a high recurrence rate of giant cells in the treatment of bone and individual sarcoidosis, and atypical femoral fractures, which need to be adequately solved.

地诺单抗是一种单克隆抗体，靶向并抑制核因子-κB 配体 (RANKL) 的破骨细胞激活因子受体激活剂。它已广泛用于治疗骨质疏松症、骨巨细胞瘤和预防恶性骨骼相关事件（SREs）。我们分别通过 Web of Science 和 PubMed 收集了 2011 年至 2021 年地诺塞麦的研究结果和相关 MeSH 术语。通过 CiteSpace 和文献计量在线分析平台对文献进行可视化和分析。使用书目共现分析系统 (BICOMB) 和图形聚类工具包 (gCLUTO) 对 MeSH 术语进行双聚类。结果显示，与狄诺塞麦相关的年度出版物数量从51篇增加到215篇，美国领先，安进公司。是近10年来最有影响力的。发表在《骨与矿物研究杂志》上的文章总被引次数最高。松本信州大学的三位学者中村由纪夫、铃木孝子和加藤博之加入该领域较晚，但产出最多。狄诺塞麦与其他药物治疗骨质疏松症的临床比较和联合是最重要的研究热点。近期药物停药反弹及管理策略受到更多关注和争议。MeSH 分析揭示了八大类研究热点。其中，探索RANK-RANKL-OPG系统在肿瘤进展、转移等疾病中的多重作用是未来机制研究的潜在方向。优化脊柱内固定和骨科假体植入的围手术期给药策略是一个有价值的外科课题。综合起来，狄诺塞麦的优势广泛且具有成本效益。但仍存在下颌骨坏死、严重低钙血症、骨及个体结节病治疗中巨细胞复发率高、非典型股骨骨折等问题，亟待解决。